Grisham, R., Monk, B. J., Van Nieuwenhuysen, E., Moore, K. N., Fabbro, M., O'Malley, D. M., . . . Banerjee, S. (2025). GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer. International journal of gynecological cancer, 35(11), 101832. https://doi.org/10.1136/ijgc-2024-005919
Citácia podle Chicago (17th ed.)Grisham, Rachel, et al. "GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A Phase 3, Randomized Trial Evaluating Avutometinib Plus Defactinib Compared with Investigator's Choice of Treatment in Patients with Recurrent Low Grade Serous Ovarian Cancer." International Journal of Gynecological Cancer 35, no. 11 (2025): 101832. https://doi.org/10.1136/ijgc-2024-005919.
Citácia podľa MLA (8th ed.)Grisham, Rachel, et al. "GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A Phase 3, Randomized Trial Evaluating Avutometinib Plus Defactinib Compared with Investigator's Choice of Treatment in Patients with Recurrent Low Grade Serous Ovarian Cancer." International Journal of Gynecological Cancer, vol. 35, no. 11, 2025, p. 101832, https://doi.org/10.1136/ijgc-2024-005919.